EdwardJBastyrMD

PubMed

• 11 citations
  The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro
  Sreekumar G. Pillai, Suman Duvvuru, Pallav Bhatnagar, Wendra M. Foster, M Farmen, Sudha S. Shankar, C Harris, Edward J. Bastyr, Byron J. Hoogwerf, Axel Haupt> ;The Pharmacogenomics Journal. 2018 May 22
• Time-Averaged Self-Monitored Blood Glucose Values Estimate Hemoglobin A1c Outcomes in Patients With Type 1 Diabetes.
  Shuyu Zhang, Ludi Fan, Qianyi Zhang, Annette M. Chang, Edward J. Bastyr, Cynthia J. Harris> ;Journal of Diabetes Science and Technology. 2018 Mar 7
• 2 citations
  Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
  Arun J. Sanyal, Kenneth Cusi, Mark L. Hartman, Shuyu Zhang, Edward J. Bastyr, Juliana M. Bue-Valleskey, Annette M. Chang, Axel Haupt, Scott J. Jacober, Robert J. Konra...> ;Journal of Investigative Medicine. 2018 Mar 1
• 203 citations
  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
  Juan Pablo Frias, Edward J. Bastyr, Louis Vignati, Matthias H. Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Bojesen Christensen, Richard D. DiMarchi> ;Cell Metabolism. 2017 Aug 1
• 16 citations
  Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
  Henry N. Ginsberg, Bertrand Cariou, Trevor J. Orchard, Lei Chen, Junxiang Luo, Edward J. Bastyr, Juliana M. Bue-Valleskey, Annette M. Chang, Tibor Ivanyi, Scott J. Jac...> ;Diabetes, Obesity & Metabolism. 2016 Nov 1
• 10 citations
  Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
  Julio Rosenstock, Michel Marre, Yongming Qu, Shuyu Zhang, Edward J. Bastyr, Melvin J. Prince, Annette M. Chang> ;Diabetes, Obesity & Metabolism. 2016 Nov 1
• 26 citations
  Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 di...
  R M Bergenstal, H Lunt, E Franek, F Travert, J Mou, Y Qu, C J Antalis, M L Hartman, M Rosilio, S J Jacober, E J Bastyr 3rd> ;Diabetes, Obesity & Metabolism. 2016 Nov 1
• 28 citations
  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
  Kenneth Cusi, Arun J. Sanyal, Shuyu Zhang, Byron J. Hoogwerf, Annette M. Chang, Scott J. Jacober, Juliana M. Bue-Valleskey, A. N. Higdon, Edward J. Bastyr, Axel Haupt,...> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• 18 citations
  Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials.
  Edward J. Bastyr, Shuyu Zhang, Jiani Mou, Andy P. Hackett, Stephen A. Raymond, Annette M. Chang> ;Diabetes Technology & Therapeutics. 2015 Aug 3
• 16 citations
  Effect of Ruboxistaurin on Albuminuria and Estimated GFR in People With Diabetic Peripheral Neuropathy: Results From a Randomized Trial
  Katherine R. Tuttle, Janet B. McGill, Edward J. Bastyr, Keri Kles Poi, Nazila Shahri, Pamela W. Anderson> ;American Journal of Kidney Diseases. 2015 Apr 1
• 25 citations
  Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine
  Richard M. Bergenstal, Julio Rosenstock, Edward J. Bastyr, Melvin J. Prince, Yongming Qu, Scott J. Jacober> ;Diabetes Care. 2014 Mar 1
• 67 citations
  The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with typ...
  Guillermo E. Umpierrez, T. Blevins, Julio Rosenstock, C. Cheng, James H. Anderson, Edward J. Bastyr> ;Diabetes, Obesity & Metabolism. 2011 May 1
• 88 citations
  Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity.
  Peter J. Dyck, Jane E. Norell, Hans J. Tritschler, Klemens Schuette, Rustem Samigullin, Dan Ziegler, Edward J. Bastyr, William J. Litchy, Peter C. O'Brien> ;Diabetes Care. 2007 Oct 1
• 39 citations
  Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials.
  Solomon Tesfaye, Rup Tandan, Edward J. Bastyr, Keri A Kles, Vladimir Skljarevski, Karen L. Price> ;Diabetes Care. 2007 Oct 1
• 23 citations
  Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom.
  Annalisa Rubino, Matthew D. Rousculp, Kimberly Davis, Jianmin Wang, Edward J. Bastyr, Solomon Tesfaye> ;Primary Care Diabetes. 2007 Sep 1
• 79 citations
  A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flo...
  Carolina Casellini, Patricia M. Barlow, Amanda L. Rice, Melissa Casey, Kathryn Simmons, Gary L. Pittenger, Edward J. Bastyr, Anne M. Wolka, Aaron I. Vinik> ;Diabetes Care. 2007 Apr 1
• 31 citations
  Clinical safety of the selective PKC-β inhibitor, ruboxistaurin
  Janet B. McGill, George L. King, Paul Berg, Karen L. Price, Keri A Kles, Edward J. Bastyr, David L. Hyslop> ;Expert Opinion on Drug Safety. 2006 Oct 18
• 40 citations
  Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy
  Aaron I. Vinik, Vera Bril, William J. Litchy, Karen L. Price, Edward J. Bastyr> ;Muscle & Nerve. 2005 Nov 1
• 111 citations
  Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, d...
  Aaron I. Vinik, Vera Bril, Péter Kempler, William J. Litchy, Solomon Tesfaye, Karen L. Price, Edward J. Bastyr> ;Clinical Therapeutics. 2005 Aug 1
• 125 citations
  Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy
  Edward J. Bastyr, Karen L. Price, Vera Bril> ;Clinical Therapeutics. 2005 Aug 1
• 152 citations
  The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.
  Etta J. Vinik, Risa P. Hayes, A Oglesby, Edward J. Bastyr, Patricia M. Barlow, Stephanie L. Ford-Molvik, Aaron I. Vinik> ;Diabetes Technology & Therapeutics. 2005 Jun 1
• 212 citations
  Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
  Edward J. Bastyr, C A Stuart, R G Brodows, S Schwartz, C J Graf, A Zagar, K E Robertson> ;Diabetes Care. 2000 Sep 1
• 21 citations
  Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro.
  Edward J. Bastyr, Y. Huang, R. L. Brunelle, Louis Vignati, D. J. Cox, J. G. Kotsanos> ;Diabetes, Obesity & Metabolism. 2000 Jan 1
• 36 citations
  Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
  Edward J. Bastyr, Martin E. Johnson, Michael E. Trautmann, James H. Anderson, Louis Vignati> ;Clinical Therapeutics. 1999 Oct 1
• 143 citations
  Metabolic and immunologic effects of insulin lispro in gestational diabetes.
  Lois Jovanovic, S. Ilic, David J. Pettitt, K. Hugo, M Gutierrez, Ronald R. Bowsher, Edward J. Bastyr> ;Diabetes Care. 1999 Sep 1
• Join now to see all

Journal Articles

• A Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 ...  
  Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Qu Y, Antalis CJ, Hartman ML, Rosilio M, Jacober SJ, Bastyr EJ III and on behalf of the IMAGINE 3 Trial Investigators, Diabetes, Obesity and Metabolism, 1/1/2016
• Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 dia...  
  Blevins T, Pieber TR, Colon Vega G, Zhang S, Bastyr EJ III, Chang AM and on behalf of the IMAGINE 4 Investigators, Diabetes, Obesity and Metabolism, 1/1/2016
• A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAG...  
  Garg S, Dreyer M, Jinnouchi H, Mou J, Qu Y, Hartman ML, Rosilio M, Jacober SJ, Bastyr EJ III and on behalf of the IMAGINE 1 Trial Investigators, Diabetes, Obesity and Metabolism, 1/1/2016
• Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials  
  Ginsberg H, Cariou B, Orchard TJ, Chen L, Luo J, Bastyr EJ III, Bue-Valleskey J, A.M. Chang AM, T. Ivanyi T, S.J. Jacober SJ, B.J. Hoogwerf BJ, Diabetes, Obesity and Metabolism, 1/1/2016
• Reduced Nocturnal Hypoglycemia with Basal Insulin Peglispro Compared to Insulin Glargine (GL): Pooled Analyses of 5 Randomized Controlled Trials  
  Rosenstock J, Marre M, Qu Y, Zhang S, Bastyr EJ III, Prince MJ, Chang AM, Diabetes, Obesity and Metabolism, 1/1/2016
• Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes  
  Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM,Higdon AN, Bastyr EJ III, Haupt A and Hartman ML, Diabetes, Obesity and Metabolism, 1/1/2016
• The PNPLA3 I148M Variant is Associated with Transaminase Elevations in Type 2 Diabetes (T2D) Patients Treated with Basal Insulin Peglispro (BIL)  
  Pillai S, Duvvuru S, Bhatnagar P, Foster W, Farmen M, Shankar S, Harris C, Bastyr EJ III, Hoogwerf B, and A Haupt, The Pharmacogenomics Journal, 1/1/2016
• Effect of Ruboxistaurin on Albuminuria and Estimated GFR in People With Diabetic Peripheral Neuropathy: Results From a Randomized Trial  
  Tuttle KR, McGill JB, Bastyr EJ, Poi KK, Shahri N, & Anderson, PW, American Journal of Kidney Diseases, 1/1/2015
• Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials  
  Bastyr EJ III, Zhang S, Mou J, Hackett AP, Raymond SA and AM Chang on behalf of the Basal Insulin Peglispro ePRO Collaboration Team, Diabetes Technology and Therapeutics, 1/1/2015
• Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine  
  Bergenstal RM, Rosenstock J, Bastyr EJ III, Prince MJ, Qu Y, Jacober SJ, Diabetes Care, 1/1/2013
• The Effects of LY2189265, a Long-acting Glucagon-Like Peptide-1 Analog, in a randomized, placebo-controlled, double-blind study of Overweight/Obese patients with type ...  
  Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, and Bastyr EJ III, Diabetes, Obesity and Metabolism, 1/1/2011
• A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of protein kinase C-b inhibitor ruboxistaurin on skin microvascular blood flow an...  
  Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ III, Wolka AM, and AI Vinik, Diabetes Care, 1/1/2007
• Diagnosis of Diabetic Peripheral Neruopathy Among Patients with Type 1 and Type 2 Diabetes in France, Italy, Spain, and the United Kingdom  
  Rubino A, Rousculp M, Davis K, Wang J, Bastyr EJ, Tesfaye S, Primary Care Diabetes, 1/1/2007
• Factors the Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials  
  Tesfaye S, Tanden R, Bastyr EJ III, Kles KA, Skljarevski V, Price KL, Ruboxistaurin Study Group, Diabetes Care, 1/1/2007
• Challenges in Design of Multicenter Trials  
  Dyck PJ, Norell JE, Tritschler H, Schuette K, Samiguillin R, Ziegler D, Bastyr EJ III, Litchy WJ, O’Brien PC, Diabetes Care, 1/1/2007
• Clinical Safety of the PKC-Beta Inhibitor, Ruboxistaurin  
  McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL, Expert Opinion in Drug Safety, 1/1/2006
• Development and Validity Testing of the Neuropathy Total Symptom Score–6: Questionnaire for the Study of Sensory Symptoms of Diabetic Peripheral Neuropathy  
  Bastyr EJ, Price KL, Bril V for the MBBQ Study Group, Clin Ther, 1/1/2005
• The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy  
  Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P. Ford-Molvik SL. Vinik AI, Diabetes Technology & Therapeutics, 1/1/2005
• Treatment of Symptomatic Diabetic Peripheral Neuropathy with the Protein Kinase C Beta-Inhibitor Ruboxistaurin Mesylate During a One-Year Randomized, Placebo-Controlle...  
  Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ III for the MBBQ Study Group, Clin Ther, 1/1/2005
• Factors Associated with Nocturnal Hypoglycemia Among patients with Type 2 Diabetes New to Insulin Therapy: Experience with Insulin Lispro  
  Bastyr EJ, Juang Y, Brunelle R, Vignati L, Cox D, Kotsanos JG, J. of Diabetes, Obesity and Metabolism, 1/1/2000
• Therapy Focused on Lowering Postprandial Glucose, Not Fasting Glucose, May be Superior for Lowering HbA1c  
  Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf C, Zagar A, Robertson KE, IOEZ Study Group, Diabetes Care, 1/1/2000
• Safety of insulin lispro: Pooled data from clinical trials  
  Glazer B, Zalani S, Symanowski S, Uminger G, Anderson JH, and EJ Bastyr, Am J Health-Syst Pharm, 1/1/1999
• The Metabolic and Immunologic Effects of Insulin Lispro in Gestational Diabetes  
  Jovanovic L, Ilic S, Pettit D, Bowsher R, Bastyr EJ, Diabetes Care, 1/1/1999
• Insulin Lispro: A New Rapid Acting Insulin  
  Prince MJ and EJ Bastyr, Contemporary Internal Medicine, 1/1/1997
• Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin  
  Anderson JH, Brunelle RL, Koivisto, V.A., Pfützner, A, Trautmann ME, Vignati L, DiMarchi R., and the Multicenter Insulin Lispro Study Group, Diabetes, 1/1/1997
• Join now to see all

Abstracts/Posters

• Greater HbA1c Reduction with Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in an Open-label, Randomized Study in T1D Patients (pts): IMAGINE 1
  Garg SK, Jinnouchi H, Dreyer M, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 1 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
• Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) and Preprandial Insulin Lispro in a Double-blind Study in Patients (pts) with Type...
  Blevins T, Pieber TR, Vega GC, Zhang S, Bastyr EJ III, Chang AM, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
• Superior Reduction of HbA1c in a Double-blind, Randomized Study of Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in Patients (pts) with T1D: IMAGINE 3
  Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 3 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
• Liver Enzyme Results from 7 Basal Insulin Peglispro (BIL) Clinical Trials in T1D and T2D
  Hartman ML, Zhang S, Bastyr EJ III, Chang AM, Jacober SJ, Prince MJ, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
• Lipid Changes During 26-Wk Treatment with the Novel Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) or Insulin NPH in 6 IMAGINE Trials
  Ginsberg H, Cariou B, Orchard TJ, Chen L, Luo J, Bastyr EJ III, Bue-Valleskey J, Chang AM, Iványi T, Jacober SJ, Jacobson JG, Hoogwerf BJ, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
• Reduced Nocturnal Hypoglycemia (Hypo) with Basal Insulin Peglispro (BIL) Compared to Insulin Glargine (GL): Pooled Analyses of 5 Randomized
  Rosenstock J, Marre M, Qu Y, Jacober SJ, Prince MJ, Chang AM, Bastyr EJ III, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
• Liver Enzyme and Liver Fat Content (LFC) Results from 7 Basal Insulin Peglispro (BIL) Clinical Trials in T1D and T2D
  Hartman ML, Zhang S, Bastyr EJ III, Chang AM, Jacober SJ, Prince MJ, European Association for the Study of Diabetes; Diabetologia, Stockholm Sweden, 1/1/2015
• Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) and Preprandial Insulin Lispro in a Double-blind Study in Type 2 Diabetes patients...
  Chang AM, Blevins T, Pieber TR, Vega Colon G, Zhang S, Bastyr EJ III, European Association for the Study of Diabetes; Diabetologia, Stockholm Sweden, 1/1/2015
• Greater HbA1c Reduction with Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) in an Open-label, Randomised Study in type 1 diabetes patients: IMAGINE 1
  Garg SK, Jinnouchi H, Dreyer M, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 1 Study Group, European Association for the Study of Diabetes; Diabetologia, Stockholm Sweden, 1/1/2015
• Reduced Nocturnal Hypoglycemia (Hypo) with Basal Insulin Peglispro (BIL) Compared to Insulin Glargine (GL): Pooled Analyses of 5 Randomized
  Marre M, Rosenstock J, Qu Y, Jacober SJ, Prince MJ, Chang AM, Bastyr EJ III, European Association for the Study of Diabetes; Diabetologia, Stockholm Sweden, 1/1/2015
• Lipid Changes During 26-Wk Treatment with the Novel Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) or Insulin NPH in 6 IMAGINE Trials
  Hoogwerf BJ, Ginsberg H, Cariou B, Orchard TJ, Chen L, Luo J, Bastyr EJ III, Bue-Valleskey J, Chang AM, Iványi T, Jacober SJ, Jacobson JG, European Association for the Study of Diabetes; Diabetologia, Stockholm Sweden, 1/1/2015
• Superior Reduction of HbA1c in a Double-blind, Randomized Study of Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in Patients (pts) with T1D: IMAGINE 3
  Lunt H, Bergenstal RM, Franek E, Travert F, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 3 Study Group, European Association for the Study of Diabetes; Diabetologia, Stockholm Sweden, 1/1/2015
• Electronic data capture in insulin management for patients with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus in global clinical trials
  Bastyr EJ, Chang A, Mou J, Bue-Valleskey J, Hamilton R, Leseniewski S, Zhang S, Prince M, American Diabetes Association National Meeting; Diabetes, San Francisco, CA, 1/1/2014
• Comprehensive electronic data capture of diabetes management information in a diverse population across 25 countries
  Chang AM, Zhang S, Hackett A, Raymond SA, Findlay B, Bastyr EJ, American Diabetes Association National Meeting; Diabetes, San Francisco, CA, 1/1/2014
• Electronic Diary Utilizaton in Clinical Trials Implementing Intensive InsulinTherapy
  Bastyr EJ, Chang A, Hackett A, Raymond SA, Hamilton R, Zhang S, Dallabrida S, Diabetes Technology Society Annual Meeting, San Francisco, CA, 1/1/2013
• The Novel Long-Acting Insulin LY2605541 Is Superior to Insulin Glargine in Lowering Intra-Day Glucose Variability and Hypoglycemia Event Rate from Continuous Glucose M...
  Bastyr EJ, Bergenstal R, Rosenstock J, Prince MJ, Qu Y, Jacober SJ, American Diabetes Association National Meeting; Diabetes, 1/1/2012
• Lower Glucose Variability and Hypoglycaemia Measured by Continuous Glucose Monitoring with Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine
  Bastyr EJ, Bergenstal R, Rosenstock J, Prince MJ, Qu Y, Jacober SJ, European Association for the Study of Diabetes; Diabetologia, Berlin, Germany, 1/1/2012
• The Impact of Hispanic Ethnicity on the Response to LY2189265 (GLP-1 Analog) Treatment of Uncontrolled Type2 Diabetes Mellitus (T2DM) Patients: an EGO Study Analysis
  Bastyr EJ, Noriega J, Botros FT, Threlkeld R, Shu J, Anderson JH, Glass L, American Diabetes Association National Meeting; Diabetes; European Association for the Study of Diabetes, Stockholm, Sweden, 1/1/2010
• The Impact of LY2189265 (GLP-1 Analog) on Glycemic Control in Hispanic and Non-hispanic Caucasians With Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients: an EGO S...
  Noriega J, Botros FT, Threlkeld R, Shu J, Anderson JH, Glass L, Bastyr EJ, American Federation of Medical Research; Journal of Investigative Medicine, 1/1/2010
• The Impact of LY2189265 (GLP-1 Analog) on Glycemic Control in Hispanic and Non-Hispanic Caucasians With Uncontrolled Type 2 Diabetes: an EGO Study Analysis
  Bastyr EJ, Noriega J, Botros FT, Threlkeld R, Shu J, Anderson JH, Glass L, American Association of Clinical Endocrinology, Boston, MA, 1/1/2010
• The Impact of Hispanic Ethnicity and the Titration Effect of LY2189265, a Glucagon-Like Peptide 1 Analog, on Metabolic Outcome Measures in Patients with Uncontrolled T...
  Bastyr EJ, Cheng CL, Noriega JE, Thompson AB, Threlkeld RJ, Shu J, Glass LC, Endocrine Society; Endocrine Reviews, San Diego, CA, 1/1/2010
• Analysis of Amylase and Lipase Levels in Type 2 Diabetes Patients Assessed during A Randomized Clinical Trial: The EGO Study
  Bastyr EJ, Cheng CL, Thompson AB, Shu J, Endocrine Society; Endocrine Reviews, San Diego, CA, 1/1/2010
• Frequent Pancreatic Amylase and Lipase Elevations in Type 2 Diabetes Mellitus
  Bastyr EJ, Cheng C, Hall N, American Diabetes Association National Meeting; Diabetes, New Orleans, LA, 1/1/2009
• Titration Effect of LY2189265 (GLP-1 analog) Once Weekly on Metabolic Outcomes and GI Events in Uncontrolled Diabetes Mellitus Type 2 (DM2): The EGO Study
  Umpierrez G, Blevins T, Rosenstock J, Cheng C, Bastyr E, and J Anderson for the EGO Study Group, American Diabetes Association National Meeting; Diabetes, New Orleans, LA, 1/1/2009
• The Effect of LY2189265 (GLP-1 analog) Once Weekly on HbA1c
  Umpierrez G, Blevins T, Rosenstock J, Cheng C, Bastyr E, and J Anderson for the EGO Study Group, European Association for the Study of Diabetes; Diabetologia, Vienna, Austria, 1/1/2009
• Join now to see all

Lectures

• Electronic Data Capture in Insulin Management for Patients (pts) with Type 1 (T1DM) and Type 2 (T2DM) Diabetes Mellitus in Global Clinical Trials 
  Indianapolis, IN - 6/14/2014
• LY2605541, A Novel Long-Acting Basal Insulin Analog 
  Colegio de Medicos de España, Madrid, Spain - 1/1/2012
• Postprandial Blood Glucose is a Better Predictor of Overall Metabolic Control in Diabetes Mellitus 
  Norfolk, VA - 1/1/2000
• The Chronic Complications of Diabetes 
  Norfolk, VA - 1/1/2000
• Diabetic Neuropathies 
  Knoxville, TN - 1/1/1999
• Polyphosphoinositide Hydrolysis and Protein Kinase C activation in platelet hyperaggregation in IDDM 
  Galveston, TX - 1/1/1992
• Join now to see all